On September 10, Oracle fell 3.05% in regular trading, trading at approximately $156.22 per share, with turnover of $9.88 billion. The decline came just hours before the company was set to report its FY2027 first fiscal quarter earnings after the close.

Multiple headwinds converged to pressure the stock. Scotiabank cut its target price from $241 to $215 while maintaining a Sector Outperform rating. Meanwhile, the options market flashed a distinctly bearish signal, with a $7.01 million bear call spread and a $317,400 synthetic short position indicating institutional funds are betting on limited upside.

The core concern centers on Oracle's balance sheet. The company spent $55.7 billion in capex during FY2026 against only $32 billion in operating cash flow, producing negative $23.7 billion in free cash flow. Management has guided net capex of approximately $70 billion for FY2027, to be partly funded by $40 billion in debt and equity. S&P has downgraded Oracle's credit rating to BBB-, just one notch above junk, with CDS costs running roughly four times those of Microsoft. Consensus expects Q1 revenue of $19.1 billion and adjusted EPS of $1.74, both within guidance, but investors are focused on whether massive backlog orders can convert into cash flow fast enough to justify the spending.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)